OrthoPediatrics (KIDS) Q3 Results Spotlight Margin Rebuild After Record Revenue

OrthoPediatrics slipped 2.1% to close at US$30.87 today, yet the fresh Q3 2026 report reads very differently from that modest pullback. The company just posted record quarterly revenue of US$72.7m and its highest adjusted earnings before interest, tax, depreciation and amortisation at US$6.9m, with an EBITDA margin near 10%.

In the short term, that mix of strong sales and improving profitability has not sparked a surge in the share price. For investors thinking in years rather than days, the sharper focus now falls on how far this margin rebuild can run from here.

Love OrthoPediatrics’ record Q3 revenue and improving EBITDA margin but want a wider set of high quality healthcare peers with strong balance sheets and fundamentals? Compare KIDS against our list of solid balance sheet and fundamentals stocks (25 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$72.7m vs. US$61.3m (record quarterly sales with double digit year on year growth)
• Net Loss (Q3 2026 vs. Q3 2025): US$5.93m loss vs. US$11.77m loss (loss narrowed compared with the prior comparable period)
• Basic EPS (Q3 2026 vs. Q3 2025): US$0.25 loss per share vs. US$0.50 loss per share (per share loss reduced year on year)
• Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): approximately 10% vs. approximately 10% (record adjusted EBITDA of US$6.9m with margin roughly in line with the prior year)

OrthoPediatrics raised revenue guidance after a record quarter. Ask Charlie what makes OrthoPediatrics’ Super Cycle growth look durable.

OrthoPediatrics Bull Case Meets Early Execution Tests

Supporters argue OrthoPediatrics can turn its product and clinic pipeline into a sturdier, higher margin engine. That view hangs on OPSB and surgeon engagement doing the heavy lifting.

"The successful scaling of the OPSB specialty bracing franchise, with both greenfield and Acquihire clinic expansions, indicates high demand and strong synergies with the core implant business. This provides a capital-efficient avenue for recurring revenue, improved operational leverage, and margin expansion in future periods."

Q3 OPSB growth above 20%, a clinic network above 60 sites and a record 10% adjusted EBITDA margin all point in the right direction. Net losses, although narrower, show the margin story is still incomplete.

OrthoPediatrics Bear Case: Profit Strain Still Visible

The cautious view is that OrthoPediatrics is stretching its cost base faster than earnings, so expansion could prolong losses instead of easing them.

"The company's aggressive OPSB clinic expansion strategy entails high upfront costs and increased operating expenses, as evidenced by an 18% year-over-year rise in total operating expenses and a continued net loss in Q2 2025. If this geographic and operational scaling fails to deliver sufficient patient flow or profitability, it may pressure earnings and delay sustainable free cash flow."

Q3 Opex rose to US$58.2m and the business still reported a net loss, even with record EBITDA. Positive quarterly free cash flow and lower impairment charges help, yet do not fully resolve the profitability concern.

The price and this Narrative do not agree. → Uncover what this Narrative says OrthoPediatrics is actually worth.

Hunt For Quiet Mispricings

OrthoPediatrics just showed that a cleaner margin story does not always move the share price on cue. The real opportunity could sit in stocks where fundamentals and expectations have clearly slipped out of sync.

• Company 1 - 34% below our estimate - uses long term optical and solar supply contracts and customer prepayments to convert a large infrastructure order book into higher operating returns.
• Company 2 - 35% below our estimate - sells the accelerated computing platform customers choose when they commit heavily to an integrated AI hardware and software stack for data centres.
• Company 3 - 46% below our estimate - converts a near record construction backlog and new higher margin mega projects into cash while working through costly legacy legal disputes.

Three companies from the same screener. Open the full list of 29 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com